Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.49 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20120719 | 1.00 | EPHX2 (0.49) | EPHX2ACKR3BCHESIGMAR1TEAD3 | |
| SCHEMBL20120662 | 0.94 | CHRM2 (0.46) | EPHX2ACKR3BCHESIGMAR1CHRM2 | |
| SCHEMBL20120659 | 0.94 | CHRM2 (0.46) | EPHX2ACKR3BCHESIGMAR1CHRM2 | |
| SCHEMBL28868788 | 0.87 | BCHE (0.50) | ACKR3BCHESIGMAR1TEAD3HRH2 | |
| SCHEMBL21751831 | 0.87 | HRH2 (0.46) | EPHX2ACKR3BCHESIGMAR1TEAD3 | |
| SCHEMBL20133160 | 0.84 | STS (0.47) | BCHE | |
| SCHEMBL20132907 | 0.82 | PRMT5 (0.45) | BCHE | |
| SCHEMBL21906846 | 0.81 | GPR119 (0.47) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13568031 | 0.81 | GPR119 (0.47) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL21906848 | 0.81 | GPR119 (0.47) | CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240091204-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230086457-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-06 | — | — | US | disclosed |
| US-11458123-B2 | Tau-protein targeting PROTACs and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3999182-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20200085793-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2020-03-19 | — | — | US | disclosed |
| WO-2020041331-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | ARVINAS OPERATIONS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | EPHX2 3391/4885ACKR3 4688/4885BCHE 1382/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | EPHX2 3301/4885ACKR3 4744/4885BCHE 1499/4885 |
| US-20240091204-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | UCHL1, ADRM1, CRBN | EPHX2 2487/4885ACKR3 4844/4885BCHE 1016/4885 |
| US-20230086457-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | EPHX2 2978/4885ACKR3 4468/4885BCHE 1930/4885 |
| US-20200085793-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | UCHL1, ADRM1, CRBN | EPHX2 2487/4885ACKR3 4844/4885BCHE 1016/4885 |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ADRM1, CRBN, SNCA | EPHX2 3644/4885ACKR3 4351/4885BCHE 2391/4885 |
| US-11458123-B2 | Tau-protein targeting PROTACs and associated methods of use | CRBN, VHL, UBQLN2 | EPHX2 2978/4885ACKR3 4468/4885BCHE 1930/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | EPHX2 2978/4885ACKR3 4468/4885BCHE 1930/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | EPHX2 3391/4885ACKR3 4688/4885BCHE 1382/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | EPHX2 4263/4885ACKR3 4191/4885BCHE 2046/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | EPHX2 2487/4885ACKR3 4844/4885BCHE 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.